Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluzoparib + famitinib
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
fluzoparib + famitinib is a combination therapy being evaluated for the maintenance treatment of advanced ovarian cancer. Fluzoparib (also known as fuzuloparib or SHR3162) is an orally active small molecule inhibitor of poly(ADP-ribose) polymerase (PARP), specifically targeting PARP1 and PARP2 to impede DNA damage repair in cancer cells. Famitinib (famitinib malate) is a multi-targeted tyrosine kinase inhibitor (TKI) that primarily inhibits vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor (PDGFR), and c-Kit, thereby exerting anti-angiogenic and anti-tumor effects. The combination is developed by Jiangsu Hengrui Pharmaceuticals and has been studied in clinical trials sponsored by investigators such as Jinhua Zhou to assess its efficacy in patients who have achieved a response to first-line platinum-based chemotherapy.
- Other names
- fuzuloparib + famitinibSHR3162 + famitinib
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR3 (Vascular endothelial growth factor receptor 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)RET (Rearranged during transfection receptor tyrosine kinase)FLT3 (Fms related receptor tyrosine kinase 3)PARP2 (Poly (adp-ribose) polymerase 2)
Beyond the preview
Go deeper on fluzoparib + famitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluzoparib + famitinib.